Quantcast

Latest Paclitaxel Stories

2014-06-20 16:22:56

SAN DIEGO, June 20, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento"), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that Henry Ji, Ph.D., President and Chief Executive Officer of Sorrento, will present at the BIO Business Forum, taking place June 23(rd)-26(th), 2014 in San Diego, CA. The presentation will take place in the Imperial Beach Presentation Room on Tuesday, June 24 at 2:45 pm...

2014-06-12 23:00:57

Health Canada has reinstated Biolyse Pharma’s Establishment Licence (EL) after sending in a team of inspectors to look at manufacturing within the St.Catharines based Pharmaceutical. The new team of inspectors found Biolyse to be in compliance with Canadian Good Manufacturing Practices (GMP) and assigned the company a "C" (conformance) rating. St.Catharines, Ontario (PRWEB) June 12, 2014 The Establishment Licensing Unit of Health Canada announced today that as a result of a...

2014-06-09 23:06:19

Transparency Market Research added a new report "Drug Eluting Balloons Market: Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2013 - 2019" to its report store. Browse the full report: http://www.transparencymarketresearch.com/drug-eluting-balloons-market.html Albany, NY (PRWEB) June 09, 2014 There are different types of cardiac stents, such as drug eluting stents (DES) and bare metal stents (BMS) available for treating stenosis. Drug eluting stents attenuated...

2014-06-05 12:28:09

Two New Therapies Will Match Progression-Free Survival Improvements Required By Surveyed U.S. Payers for Formulary Inclusion, According to a New Report from Decision Resources Group BURLINGTON, Mass., June 5, 2014 /PRNewswire/ -- Decision Resources Group finds that in addition to an improvement in median overall survival (MOS), delayed disease progression is one of the greatest unmet needs in the first-line treatment of advanced ovarian cancer (CaO). MOS and disease progression are also key...

2014-05-30 16:24:41

SAN DIEGO, May 30, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced that Henry Ji, Ph.D., President and Chief Executive Officer of Sorrento, will present at the Jefferies 2014 Global Healthcare Conference. The presentation will take place at 8:00 am EDT on Wednesday, June 4, 2014 at the Grand Hyatt, New York. A live webcast of the presentation can...

2014-05-23 11:04:04

Berkeley Lab Berkeley Lab Researchers Take an Atomic-Scale Look at Key Cellular Protein A pathway to the design of even more effective versions of the powerful anti-cancer drug Taxol has been opened with the most detailed look ever at the assembly and disassembly of microtubules, tiny fibers of tubulin protein that form the cytoskeletons of living cells and play a crucial role in mitosis. Through a combination of high-resolution cryo-electron microscopy (cryo-EM) and new methodology for...

2014-05-20 23:02:55

New comprehensive research report “Ovarian Cancer Therapeutics in Major Developed Markets to 2020 - Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies” elaborated by GBI Research is now available at MarketPublishers.com. According to the study, the global ovarian cancer therapeutics market is anticipated to post a 3.4% CAGR through 2020. London, UK (PRWEB) May 20, 2014 At present, the overall ovarian cancer therapeutics market is led by the use of...

2014-05-20 08:34:22

AADi Initiates NIH Funded Clinical Trial for Patients with Bladder Cancer PACIFIC PALISADES, Calif., May 20, 2014 /PRNewswire/ -- AADi, LLC, a clinical stage biopharmaceutical company focused on treating diseases uniquely suited for nanotechnology approaches, today announced the inlicensing of ABI-009 from Celgene Corporation (NASDAQ:CELG). ABI-009 is the nanoparticle albumin-bound (nab®) version of the mTOR inhibitor sirolimus or rapamycin and leverages the same technology of the...

2014-05-16 12:27:57

RnRMarketResearch.com adds "Ovarian Cancer Therapeutics in Major Developed Markets to 2020 - Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies" to its store. DALLAS, May 16, 2014 /PRNewswire-iReach/ -- "Ovarian Cancer Therapeutics in Major Developed Markets to 2020 Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies". The current Ovarian cancer therapeutics market is dominated by the use of generics - predominately...

2014-05-09 20:23:02

Supply of paclitaxel will not be disrupted for Canadian patients OTTAWA, May 9, 2014 /CNW/ - Health Canada today confirmed it has suspended the establishment licence of Biolyse Pharma Corporation's facility in St. Catharines, Ont., because of significant concerns with the manufacturing process discovered during a recent inspection. Injectable paclitaxel (6mg/ml), used in the treatment of certain lung and breast cancers, is currently the only drug produced at that facility....


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related